COMMUNIQUÉS West-GlobeNewswire

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
24/04/2024
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial [...]
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
24/04/2024
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, [...]
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
24/04/2024
More than Ten Operating Room Procedures Complete with Multiple Sites Reordering and Scheduling Cases SOLANA BEACH, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a [...]
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
24/04/2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for [...]
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
24/04/2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
24/04/2024
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ [...]
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
24/04/2024
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional [...]
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present [...]
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
24/04/2024
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE [...]
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed [...]
Madrigal Statement on the Passing of Dr. Stephen Harrison
24/04/2024
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. [...]
Cytokinetics to Announce First Quarter Results on May 8, 2024
24/04/2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. [...]
InnovAge Launches PACE Center in Los Angeles, Helping Seniors Live Independently with High-Quality Care
24/04/2024
Crenshaw Center Spotlights Impact of Participant-Centered, Coordinated Senior Care at No Cost to Eligible Seniors LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), the [...]
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
24/04/2024
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients DUBLIN, Ireland and BRIDGEWATER, N.J., [...]
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO ® (nirogacestat) in adults with desmoid tumors also accepted for [...]
LTC ACO Welcomes New Chief Operating Officer
24/04/2024
Country’s First Long-term Care Accountable Care Organization Appoints Michele Fronckiewicz to Executive Leadership Team KENNETT SQUARE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first Accountable Care [...]
Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format)
24/04/2024
Public release of Virbac Annual Report at 31 December 2023 (ESEF format). The Group released and filed its 2023 Annual Report with the French “Autorité des marchés financiers”. The document is also available on the [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023
24/04/2024
Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au [...]
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
24/04/2024
Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Pages